Strategies to manage retinoblastoma in developing countries
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Survival of retinoblastoma is >90% in developed countries but there are significant differences with developing countries in stage at presentation, available treatment options, family compliance, and survival. In low‐income countries (LICs), children present with advanced disease, and the reasons are socioeconomic and cultural. In middle‐income countries (MICs), survival rates are better (>70%), but there is a high prevalence of microscopically disseminated extraocular disease. Programs for eye preservation have been developed, but toxicity‐related mortality is higher. Although effective treatment of microscopically extraocular disease improved the outcome, worldwide survival will be increased only by earlier diagnosis and better treatment adherence. Pediatr Blood Cancer 2011;56:341–348. © 2010 Wiley‐Liss, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Risk of Second Malignancies in Survivors of Retinoblastoma: More Than 40 Years of Follow-up
Marees, T., Moll, A. C., Imhof, S. M., de Boer, M. R., Ringens, P. J., & van Leeuwen, F. E. (2008) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djn394 · Cited by 286
Cited by
Therapeutic targeting of the RB1 pathway in retinoblastoma with the oncolytic adenovirus VCN-01
Pascual-Pasto, G., Bazan-Peregrino, M., Olaciregui, N. G., Restrepo-Perdomo, C. A., Mato-Berciano, A., Ottaviani, D., Weber, K., Correa, G., Paco, S., Vila-Ubach, M., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aat9321 · Cited by 118
“INTRODUCTION Each year, it is estimated that 8000 cases of retinoblastoma—a tumor of the developing retina—are diagnosed worldwide, representing 11% of cancers in children less than 1 year of age (1).”
BackgroundSelf-citationUnderstanding pRb: toward the necessary development of targeted treatments for retinoblastoma
Sachdeva, U. M., & O’Brien, J. M. (2012) · Journal of Clinical Investigation · doi:10.1172/jci57114 · Cited by 67
Metadata
- Authors
- Chantada, G. L., Qaddoumi, I., Canturk, S., Khetan, V., Ma, Z., Kimani, K., Yeniad, B., Sultan, I., Sitorus, R. S., Tacyildiz, N., & Abramson, D. H.
- Venue
- Pediatric Blood & Cancer
- Publisher
- Wiley
- Published
- 2010-11-11
- Volume
- 56
- Issue
- 3
- Pages
- 341-348
- ISSN
- 1545-5009 (ISSN-L)
- 1545-5017
- OpenAlex
- W2032844416
- Cited by
- 167
- References
- 1
- FWCI
- 8.90
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.